

## **Summary of Risk Management Plan for Tadalafil Mylan (Tadalafil)**

This is a summary of the risk management plan (RMP) for Tadalafil Mylan. The RMP details important risks of tadalafil, how these risks can be minimised, and how more information will be obtained about tadalafil's risks and uncertainties (missing information).

Tadalafil Mylan's Summary of Product Characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how it should be used.

This summary of the RMP for Tadalafil Mylan should be read in the context of all the information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Tadalafil Mylan's RMP.

### **I. The Medicine and What it is Used For**

Tadalafil Mylan is indicated for the treatment of erectile dysfunction in adult males and for treatment of the signs and symptoms of benign prostatic hyperplasia in adult males. It contains tadalafil as the active substance and it is given orally.

Further information about the evaluation of Tadalafil Mylan's benefits can be found in Tadalafil Mylan's EPAR, including its plain-language summary, available on the EMA website, under the medicine's webpage <https://www.ema.europa.eu/en/medicines/human/EPAR/tadalafil-mylan>.

### **II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks**

Important risks of Tadalafil Mylan together with measures to minimise such risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the public (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse events is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

## **II.A List of Important Risks and Missing Information**

Important risks of Tadalafil Mylan are those risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered to/taken by patients. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Tadalafil Mylan. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine/use in special patient populations etc.)

### **Summary of safety concerns**

<b>List of Important Risks and Missing Information</b>	
Important Identified Risks	None
Important Potential Risks	None
Missing Information	None

## **II.B Summary of Important Risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

## **II.C Post-Authorisation Development Plan**

### **II.C.1 Studies Which are Conditions of the Marketing Authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Tadalafil Mylan.

### **II.C.2 Other Studies in Post-Authorisation Development Plan**

There are no studies required for Tadalafil Mylan.